Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses
暂无分享,去创建一个
Kylene Kehn-Hall | Aarthi Narayanan | K. Kehn-Hall | F. Kashanchi | Charles L. Bailey | Aarthi Narayanan | Fatah Kashanchi | Charles Bailey
[1] F. Hayden,et al. Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection , 2006, Antimicrobial Agents and Chemotherapy.
[2] Chi‐Huey Wong,et al. An O-glycoside of sialic acid derivative that inhibits both hemagglutinin and sialidase activities of influenza viruses. , 2002, Glycobiology.
[3] Andrzej T Galecki,et al. Prevention of influenza pneumonitis by sialic Acid-conjugated dendritic polymers. , 2002, The Journal of infectious diseases.
[4] L. Yao,et al. Production and characterization of a recombinant single-chain antibody against Hantaan virus envelop glycoprotein , 2009, Applied Microbiology and Biotechnology.
[5] Wei Zhang,et al. Inhibition of highly pathogenic avian influenza virus H5N1 replication by the small interfering RNA targeting polymerase A gene. , 2009, Biochemical and biophysical research communications.
[6] Robert Damoiseaux,et al. A broad-spectrum antiviral targeting entry of enveloped viruses , 2010, Proceedings of the National Academy of Sciences.
[7] D. Gilliland,et al. Drug therapy for acute myeloid leukemia. , 2005, Blood.
[8] M. Bray,et al. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. , 1999, The Journal of infectious diseases.
[9] H. Klenk,et al. Oligomerization of Ebola Virus VP30 Is Essential for Viral Transcription and Can Be Inhibited by a Synthetic Peptide* , 2003, Journal of Biological Chemistry.
[10] Takao Kuroda,et al. Chemoenzymatic synthesis and application of glycopolymers containing multivalent sialyloligosaccharides with a poly(L-glutamic acid) backbone for inhibition of infection by influenza viruses. , 2003, Glycobiology.
[11] R. Frank,et al. Identification of a PA-Binding Peptide with Inhibitory Activity against Influenza A and B Virus Replication , 2009, PloS one.
[12] B. Moss,et al. Amino acid substitutions at multiple sites within the vaccinia virus D13 scaffold protein confer resistance to rifampicin. , 2007, Virology.
[13] M. Paulshock,et al. Antiviral Activity of 1-Adamantanamine (Amantadine) , 1964, Science.
[14] J. A. Comer,et al. Chapare Virus, a Newly Discovered Arenavirus Isolated from a Fatal Hemorrhagic Fever Case in Bolivia , 2008, PLoS pathogens.
[15] B. Hjelle,et al. Characterization and NMR Solution Structure of a Novel Cyclic Pentapeptide Inhibitor of Pathogenic Hantaviruses , 2007, Chemical biology & drug design.
[16] V. Martinelli,et al. Mitoxantrone: benefits and risks in multiple sclerosis patients , 2009, Neurological Sciences.
[17] E. De Clercq,et al. Broad-spectrum antiviral activity of the carbocyclic analog of 3-deazaadenosine. , 1983, Antiviral research.
[18] I. Barr,et al. Oseltamivir Resistance and the H274Y Neuraminidase Mutation in Seasonal, Pandemic and Highly Pathogenic Influenza Viruses , 2012, Drugs.
[19] M. Kinch,et al. FGI-104: a broad-spectrum small molecule inhibitor of viral infection. , 2009, American journal of translational research.
[20] Erik De Clercq. Emerging antiviral drugs. , 2008, Expert opinion on emerging drugs.
[21] C. Peng,et al. Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. , 2010, Anti-cancer agents in medicinal chemistry.
[22] E. Kern,et al. In vitro and in vivo evaluation of isatin-beta-thiosemicarbazone and marboran against vaccinia and cowpox virus infections. , 2006, Antiviral research.
[23] K. Seiter. Toxicity of the topoisomerase II inhibitors , 2005, Expert opinion on drug safety.
[24] Person-to-person transmission of oseltamivir-resistant influenza A/H1N1 viruses in two households; Germany 2007/08. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[25] L. Holland,et al. Peramivir and its use in H1N1 influenza. , 2010, Drugs of today.
[26] Yoshihiro Kawaoka,et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses , 2009, Proceedings of the National Academy of Sciences.
[27] M. Bray,et al. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. , 2000, Antiviral research.
[28] D. Smee,et al. Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. , 2010, Antiviral research.
[29] T. Wilt,et al. Chemotherapy for hormone-refractory prostate cancer. , 2006, The Cochrane database of systematic reviews.
[30] D. Smee,et al. Identification of Novel Antipoxviral Agents: Mitoxantrone Inhibits Vaccinia Virus Replication by Blocking Virion Assembly , 2007, Journal of Virology.
[31] E. De Clercq. The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. , 2007, Antiviral research.
[32] E. De Clercq,et al. (S)-9-(2,3-Dihydroxypropyl)adenine: An Aliphatic Nucleoside Analog with Broad-Spectrum Antiviral Activity , 1978, Science.
[33] J. Gorchynski,et al. Acute ascending paralysis presenting as an endocrine emergency. , 2009, American Journal of Emergency Medicine.
[34] E. Reinherz,et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. , 2005, The Journal of clinical investigation.
[35] C. García,et al. Inhibition of Junín virus replication by small interfering RNAs , 2009, Antiviral Research.
[36] S. M. Amberg,et al. pH-Induced Activation of Arenavirus Membrane Fusion Is Antagonized by Small-Molecule Inhibitors , 2008, Journal of Virology.
[37] R. Charrel,et al. Arenaviruses other than Lassa virus. , 2003, Antiviral research.
[38] J. Taubenberger,et al. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[39] R. Webster,et al. Neuraminidase Inhibitor-Resistant Influenza Viruses May Differ Substantially in Fitness and Transmissibility , 2005, Antimicrobial Agents and Chemotherapy.
[40] C. García,et al. Inhibition of arenavirus infection by thiuram and aromatic disulfides. , 2010, Antiviral research.
[41] A. Siddiqui,et al. Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies , 2008, Virology.
[42] E. De Clercq,et al. Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds , 1991, Antimicrobial Agents and Chemotherapy.
[43] R. Buller,et al. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. , 2004, Virology.
[44] M. Kinch,et al. Development of a broad-spectrum antiviral with activity against Ebola virus. , 2009, Antiviral research.
[45] E. De Clercq. Vaccinia Virus Inhibitors as a Paradigm for the Chemotherapy of Poxvirus Infections , 2001, Clinical Microbiology Reviews.
[46] K. Nakai,et al. Obstructive acute renal failure related to amantadine intoxication. , 2009, The American journal of emergency medicine.
[47] D. Hruby,et al. Tecovirimat for smallpox infections. , 2010, Drugs of today.
[48] C. Peters,et al. Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans. , 1985, Vaccine.
[49] Yasuo Suzuki,et al. Simple synthesis of sialyllactose-carrying polystyrene and its binding with influenza virus , 1998, Glycoconjugate Journal.
[50] K. Borden,et al. An antiviral disulfide compound blocks interaction between arenavirus Z protein and cellular promyelocytic leukemia protein. , 2010, Biochemical and biophysical research communications.
[51] C. García,et al. Characterization of Junín virus particles inactivated by a zinc finger-reactive compound. , 2009, Virus research.
[52] S. Ludwig. Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. , 2009, The Journal of antimicrobial chemotherapy.
[53] E. Saphire,et al. Ebolavirus glycoprotein structure and mechanism of entry. , 2009, Future virology.
[54] C. Achete,et al. Cidofovir Inhibits Genome Encapsidation and Affects Morphogenesis during the Replication of Vaccinia Virus , 2009, Journal of Virology.
[55] J. Tomassini,et al. Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors , 1996, Antimicrobial agents and chemotherapy.
[56] W. Garten,et al. The role of myristoylation in the membrane association of the Lassa virus matrix protein Z , 2006, Virology Journal.
[57] G. Ruthel,et al. Antiviral Activity of a Small-Molecule Inhibitor of Filovirus Infection , 2010, Antimicrobial Agents and Chemotherapy.
[58] A. Kuehne,et al. Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques. , 1992, Intervirology.
[59] S. M. Amberg,et al. Identification of a Broad-Spectrum Arenavirus Entry Inhibitor , 2008, Journal of Virology.
[60] R. Sidwell,et al. Prophylactic and therapeutic intervention of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with interferon alfacon-1. , 2008, Antiviral research.
[61] G. Ruthel,et al. Chemical Modifications of Antisense Morpholino Oligomers Enhance Their Efficacy against Ebola Virus Infection , 2009, Antimicrobial Agents and Chemotherapy.
[62] S. Kunz,et al. Targeting the Proteolytic Processing of the Viral Glycoprotein Precursor Is a Promising Novel Antiviral Strategy against Arenaviruses , 2009, Journal of Virology.
[63] D. Smee,et al. Treatment of Late Stage Disease in a Model of Arenaviral Hemorrhagic Fever: T-705 Efficacy and Reduced Toxicity Suggests an Alternative to Ribavirin , 2008, PloS one.
[64] E. Vela,et al. Genistein treatment of cells inhibits arenavirus infection. , 2008, Antiviral research.
[65] S. Makino,et al. Rift valley fever vaccines. , 2009, Vaccine.
[66] Peter B Jahrling,et al. Exotic emerging viral diseases: progress and challenges , 2004, Nature Medicine.
[67] F. Geng,et al. Mesoionic Heterocyclic Compounds as Candidate Messenger RNA Cap Analogue Inhibitors of the Influenza Virus RNA Polymerase Cap-Binding Activity , 2009, Antiviral chemistry & chemotherapy.
[68] O. Ergonul. Treatment of Crimean-Congo hemorrhagic fever. , 2008, Antiviral research.
[69] D L Barnard,et al. In vitro and in vivo influenza virus-inhibitory effects of viramidine. , 2005, Antiviral research.
[70] John Steel,et al. Protection from the 2009 H1N1 Pandemic Influenza by an Antibody from Combinatorial Survivor-Based Libraries , 2010, PLoS pathogens.
[71] Ralph S. Baric,et al. Novel Influenza Virus NS1 Antagonists Block Replication and Restore Innate Immune Function , 2008, Journal of Virology.
[72] H. Horikawa,et al. Oseltamivir-Resistant Influenza Viruses A (H1N1) during 2007–2009 Influenza Seasons, Japan , 2010, Emerging infectious diseases.
[73] E. Saphire,et al. Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. , 2009, Current opinion in structural biology.
[74] D. Smee. Progress in the Discovery of Compounds Inhibiting Orthopoxviruses in Animal Models , 2008, Antiviral chemistry & chemotherapy.
[75] Takeshi Masuda,et al. Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir. , 2003, Bioorganic & medicinal chemistry letters.
[76] Rafael Delgado,et al. In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins. , 2004, The Journal of infectious diseases.
[77] J. Klingström,et al. An Antibody against a Novel and Conserved Epitope in the Hemagglutinin 1 Subunit Neutralizes Numerous H5N1 Influenza Viruses , 2010, Journal of Virology.
[78] D. A. Stein,et al. Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers , 2006, PLoS pathogens.
[79] A. Gronenborn,et al. The highly specific carbohydrate-binding protein cyanovirin-N: structure, anti-HIV/Ebola activity and possibilities for therapy. , 2005, Mini reviews in medicinal chemistry.
[80] Thorsten Wolff,et al. Interplay between influenza A virus and the innate immune signaling. , 2010, Microbes and infection.
[81] A. Lackenby,et al. Oseltamivir-Resistant Influenza Viruses A (H1N1), Norway, 2007–08 , 2009, Emerging infectious diseases.
[82] E. De Clercq,et al. Antiviral agents active against influenza A viruses , 2006, Nature reviews. Drug discovery.
[83] B. Hjelle,et al. Hantavirus infection. , 1998, Disease-a-month : DM.
[84] P. Iversen,et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections , 2010, Nature Medicine.
[85] M. Feinberg,et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases , 2005, Nature Medicine.
[86] Richard S. Larson,et al. Peptide Antagonists That Inhibit Sin Nombre Virus and Hantaan Virus Entry through the β3-Integrin Receptor , 2005, Journal of Virology.
[87] Philip K. Russell,et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. , 2002, JAMA.
[88] F. Linero,et al. Participation of the phosphatidylinositol 3-kinase/Akt pathway in Junín virus replication in vitro , 2009, Virus Research.
[89] C. Peters,et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. , 1999, Vaccine.
[90] J. Taubenberger,et al. Influenza: The Once and Future Pandemic , 2010, Public health reports.
[91] Deborah Ferriola,et al. Tyrosine kinase blockers: new hope for successful cancer therapy. , 2009, Anti-cancer agents in medicinal chemistry.
[92] K. Spurgers,et al. Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses , 2008, Antiviral Research.
[93] B. Lina,et al. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[94] L. Staudt,et al. Active NF-kappaB signalling is a prerequisite for influenza virus infection. , 2004, The Journal of general virology.
[95] M. Bray,et al. 3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice. , 2002, Antiviral research.
[96] Hung-Jen Liu,et al. PI3K-Akt signaling and viral infection. , 2008, Recent patents on biotechnology.
[97] H. Feldmann,et al. Prospects for immunisation against Marburg and Ebola viruses , 2010, Reviews in medical virology.
[98] R. Borchardt,et al. 9-(trans-2',trans-3'-Dihydroxycyclopent-4'-enyl)-adenine and -3-deazaadenine: analogs of neplanocin A which retain potent antiviral activity but exhibit reduced cytotoxicity , 1987, Antimicrobial Agents and Chemotherapy.
[99] G. Cristalli,et al. Antiviral properties of deazaadenine nucleoside derivatives. , 2006, Current medicinal chemistry.
[100] J. Williamson,et al. Neuraminidase Inhibitors in Patients with Underlying Airways Disease , 2002, American journal of respiratory medicine : drugs, devices, and other interventions.
[101] H. Klenk,et al. Natural and synthetic sialic acid‐containing inhibitors of influenza virus receptor binding , 2003, Reviews in medical virology.
[102] W. Ian Lipkin,et al. Genetic Detection and Characterization of Lujo Virus, a New Hemorrhagic Fever–Associated Arenavirus from Southern Africa , 2009, PLoS pathogens.
[103] James R. Smith. Oseltamivir in human avian influenza infection , 2010, The Journal of antimicrobial chemotherapy.
[104] X. de Lamballerie,et al. Arenaviruses. , 2007, Current topics in microbiology and immunology.
[105] E. Declercq. Antiviral and antitumor activities of 5-substituted 2'-deoxyuridines. , 1980 .
[106] J. Alimonti,et al. In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics. , 2007, The Journal of infectious diseases.
[107] D. Smee,et al. Triple Combination of Amantadine, Ribavirin, and Oseltamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Strains In Vitro , 2010, PloS one.
[108] Hiroki Inoue,et al. Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy. , 2010, Journal of medicinal chemistry.
[109] L. Harrison,et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. , 1998, The Journal of infectious diseases.
[110] R. Borchardt,et al. Neplanocin A. A potent inhibitor of S-adenosylhomocysteine hydrolase and of vaccinia virus multiplication in mouse L929 cells. , 1984, The Journal of biological chemistry.
[111] J. Huggins,et al. Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever , 1988, Antimicrobial Agents and Chemotherapy.
[112] E. De Clercq. Antiviral and antitumor activities of 5-substituted 2'-deoxyuridines. , 1980, Methods and findings in experimental and clinical pharmacology.
[113] D. Smee,et al. Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. , 2009, The Journal of antimicrobial chemotherapy.
[114] G. Yılmaz,et al. The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[115] K. Borden,et al. Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds. , 2006, The Journal of general virology.
[116] T. Meyer,et al. Inhibition of Marburg virus protein expression and viral release by RNA interference. , 2005, The Journal of general virology.
[117] D. A. Stein,et al. VP35 Knockdown Inhibits Ebola Virus Amplification and Protects against Lethal Infection in Mice , 2006, Antimicrobial Agents and Chemotherapy.
[118] Paolo Ascenzi,et al. Ebolavirus and Marburgvirus: insight the Filoviridae family. , 2008, Molecular aspects of medicine.
[119] S. Cordo,et al. Myristic acid analogs are inhibitors of Junin virus replication. , 1999, Microbes and infection.
[120] I. Barr,et al. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. , 2010, Antiviral research.
[121] Kevin F. Jones,et al. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses , 2005, Antiviral Research.
[122] Xiao Yan Yang,et al. Phase I Evaluation of the Safety and Pharmacokinetics of a Single-Dose Intravenous Injection of a Murine Monoclonal Antibody against Hantaan Virus in Healthy Volunteers , 2009, Antimicrobial Agents and Chemotherapy.
[123] R. K. Robins,et al. Effect of 1-β-d-Ribofuranosyl-1,2,4-Triazole-3-Carboxamide (Virazole, ICN 1229) on Herpes and Vaccinia Keratitis and Encephalitis in Laboratory Animals , 1973, Antimicrobial Agents and Chemotherapy.
[124] Brian D. Peyser,et al. Identification of Essential Filovirion-associated Host Factors by Serial Proteomic Analysis and RNAi Screen* , 2010, Molecular & Cellular Proteomics.
[125] M. Mendenhall,et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. , 2007, Antimicrobial agents and chemotherapy.
[126] J. C. de la Torre,et al. Myristoylation of the RING Finger Z Protein Is Essential for Arenavirus Budding , 2004, Journal of Virology.
[127] R. Shaw,et al. beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[128] R. Webby,et al. Mutations in the NS1 Protein of Swine Influenza Virus Impair Anti-Interferon Activity and Confer Attenuation in Pigs , 2005, Journal of Virology.
[129] Mike Bray,et al. Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. , 2003, Antiviral research.